Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome.

[5] The most common side effects include diarrhea and abdominal pain (belly ache).

[6] Maralixibat chloride was approved for medical use in the United States in September 2021,[5][7][8][9] and in the European Union in December 2022.

[6] Maralixibat chloride is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.

[14] The applicant for this medicinal product is Mirum Pharmaceuticals International B.V.[14] Maralixibat chloride was approved for medical use in the European Union in December 2022.